Zhejiang Synsorbio Technology Co., Ltd.

Guangzhou Reforgene Medicine Co., Ltd.

Kaiwei Si

Qiuting Li

Junbin Liang

Desheng Huangfu

Yang Sun

Xingxiang Liang

Hui Xu

Zhiqin Peng

The present invention relates to a CRISPR-Cas13 system and use thereof, and also relates to a Cas13 protein, a fusion protein, and a guide polynucleotide. The Cas13 protein has at least 90% sequence identity compared to SEQ ID NO: 1. The fusion protein comprises the Cas13 protein fused to a protein domain and/or a polypeptide tag. The guide polynucleotide comprises a same-direction repetition sequence and a guide sequence that has been engineered to hybridize with the target RNA. The same-direction repetition sequence has at least 70% sequence identity to any of SEQ ID NOs: 3 and 80-87. The CRISPR-Cas13 system comprises the Cas13 protein that has at least 90% sequence identity to SEQ ID NO: 1, or a coding nucleic acid therefor, and the guide polynucleotide or a coding nucleic acid therefor.

CRISPR-Cas13 system and use thereof

Growing community of inventors

Guangdong, China

Kaiwei Si